Optimizing Vitamin D in the Elderly

NCT ID: NCT01554241

Last Updated: 2015-02-18

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

86 participants

Study Classification

INTERVENTIONAL

Study Start Date

2012-09-30

Study Completion Date

2014-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Vitamin D deficiency is highly prevalent in older people in the absence of vitamin D supplementation. The limited data available show marked inter-individual variability in response to vitamin D supplementation in very old, frail elderly with almost 25% remaining vitamin D deficient (25-OH D \< 20 ng/mL) when receiving the currently recommended 800 IU/day vitamin D. This proposal is for exploratory research on the use of a wide range of oral vitamin D3 doses in frail elderly living in controlled living environments.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The investigators will determine the dose response relationship of circulating total and unbound 25-OH vitamin D3 to supplemental vitamin D3 at daily doses of 800 (currently recommended for the elderly), 2000, and 4000 IU or 50,000 IU/weekly in a randomized blinded investigation of 16 weeks duration. The investigators will also compare the efficacy of each dosing regimen in achieving 25-OH vitamin D levels \>20 ng/mL (50 nmol/L) and identify covariates that contribute to inter-individual variation in the dose response relationship. In patients with osteoporosis, relationships between unbound vs. total 25-OH on intact parathyroid hormone and a marker of bone resorption (beta-Ctx) will be analyzed. The investigators will also examine responses of inflammatory cytokines.

Note: as of April 8,2014, there will be no further enrollment in the 50,000 IU/weekly dose group

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Deficiency of Vitamin D3

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Blinding Strategy

SINGLE

Participants

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

vitamin D3 800 IU/day

recommended daily dosage of 800 IU/day D3

Group Type EXPERIMENTAL

vitamin D3 800 IU/day

Intervention Type DIETARY_SUPPLEMENT

vitamin D3 800 IU/day

2000 IU/day D3

D3 2000 IU/day

Group Type EXPERIMENTAL

D3 2000 IU/day

Intervention Type DIETARY_SUPPLEMENT

2000 IU/day D3

vitamin D3 4000 IU/day

D3 4000 IU/day

Group Type EXPERIMENTAL

D3 4000 IU/day

Intervention Type DIETARY_SUPPLEMENT

vitamin D3 4000 IU/day

50,000 IU/week D3

D3 50,000 IU weekly

Group Type EXPERIMENTAL

D3 50,000 IU weekly

Intervention Type DIETARY_SUPPLEMENT

vitamin D3 50,000 IU/week

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

D3 2000 IU/day

2000 IU/day D3

Intervention Type DIETARY_SUPPLEMENT

D3 4000 IU/day

vitamin D3 4000 IU/day

Intervention Type DIETARY_SUPPLEMENT

D3 50,000 IU weekly

vitamin D3 50,000 IU/week

Intervention Type DIETARY_SUPPLEMENT

vitamin D3 800 IU/day

vitamin D3 800 IU/day

Intervention Type DIETARY_SUPPLEMENT

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

cholecalciferol cholecalciferol cholecalciferol cholecalciferol

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* age over 65
* medically stable
* residing in long-term care or assisted living

Exclusion Criteria

* hypercalcemia or high risk for hypercalcemia
* active cancer or malignancy other than non-melanoma skin cancer
* severe renal disease (eGFR \<30 ml/mkin/M2)
* small bowel resection or intestinal bypass surgery
* hyperparathyroidism
* granulomatous disease
* clinically unstable (changes in medications or diagnoses within a month, hospitalizations, within 6 months)
* allergy to vitamin D
Minimum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University of California, San Francisco

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Janice B Schwartz, MD

Role: PRINCIPAL_INVESTIGATOR

University of California, San Francisco

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University of California

San Francisco, California, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

1R21AG04166001-A1

Identifier Type: OTHER_GRANT

Identifier Source: secondary_id

additional funder

Identifier Type: OTHER_GRANT

Identifier Source: secondary_id

DinNH2012

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

High-dose Vitamin D Supplements in Older Adults
NCT03613116 ACTIVE_NOT_RECRUITING PHASE2
Treatment of Vitamin D Insufficiency
NCT00933244 COMPLETED PHASE4